Roland Martin

Q: What Schools Are Affiliated With Roland Martin

Roland Martin is affiliated with the following schools: University of California, Berkeley, Stanford University, University of Tübingen, University of Zurich

Roland Martin's AcademicInfluence.com Rankings

Roland Martin

Computer Science

#5274

World Rank

#5571

Historical Rank

Machine Learning

#1334

World Rank

#1355

Historical Rank

Artificial Intelligence

#1571

World Rank

#1601

Historical Rank

Database

#2431

World Rank

#2548

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Roland Martin's Degrees

PhD Computer Science Stanford University
Masters Artificial Intelligence University of California, Berkeley

Similar Degrees You Can Earn

Why Is Roland Martin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roland Martin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) (2511)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis (2013) (1170)
Immunological aspects of demyelinating diseases. (1992) (1078)
Multiple sclerosis: a complicated picture of autoimmunity (2007) (1028)
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand (2000) (809)
Immunology of multiple sclerosis. (2005) (762)
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. (2006) (599)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients (2005) (466)
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways (2003) (466)
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. (1995) (410)
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. (2008) (408)
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein (1996) (398)
The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment (2012) (387)
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. (1990) (366)
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis (1995) (360)
Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone (1997) (355)
Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis (1992) (341)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. (2004) (320)
Exploring the origins of grey matter damage in multiple sclerosis (2015) (319)
Development of biomarkers in multiple sclerosis. (2004) (299)
Immunology of Multiple Sclerosis (2016) (293)
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis (1991) (285)
The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. (1998) (278)
Infectious causes of multiple sclerosis (2006) (269)
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions (1993) (267)
CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. (1994) (266)
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation (2011) (262)
Antigen-Specific Tolerance by Autologous Myelin Peptide–Coupled Cells: A Phase 1 Trial in Multiple Sclerosis (2013) (256)
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. (2002) (255)
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis (2018) (252)
Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis (2004) (247)
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2 (2008) (246)
CD4+CD28- costimulation-independent T cells in multiple sclerosis. (2001) (242)
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis (2003) (240)
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. (2010) (239)
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease (1999) (235)
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. (2006) (228)
T Lymphocyte Priming by Neutrophil Extracellular Traps Links Innate and Adaptive Immune Responses (2012) (224)
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. (2003) (218)
A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. (2009) (199)
Structure of a human autoimmune TCR bound to a myelin basic protein self‐peptide and a multiple sclerosis‐associated MHC class II molecule (2005) (199)
The immunopathogenesis of multiple sclerosis. (2002) (187)
Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. (1994) (187)
Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes (2001) (185)
Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. (1998) (184)
Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. (1998) (182)
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. (2003) (169)
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. (2009) (168)
Mechanisms of immunomodulation by glatiramer acetate (2000) (164)
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. (2013) (163)
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. (1992) (158)
Magnetic resonance imaging of labeled T‐cells in a mouse model of multiple sclerosis (2004) (156)
The value of animal models for drug development in multiple sclerosis. (2006) (155)
Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-β1 Secretion In Vivo1 (2001) (153)
Neutrophils in multiple sclerosis are characterized by a primed phenotype (2012) (153)
Probing degeneracy in T-cell recognition using peptide combinatorial libraries. (1998) (151)
Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. (2013) (149)
Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography (2012) (148)
Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events. (1999) (146)
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis (2017) (145)
T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. (1993) (143)
Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. (2000) (136)
Application of support vector machines for T-cell epitopes prediction (2003) (131)
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis (1993) (129)
Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms (2008) (121)
Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. (1997) (116)
Exploring immunological specificity using synthetic peptide combinatorial libraries. (1999) (114)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis? (2007) (112)
Molecular mimicry and multiple sclerosis: Degenerate T‐cell recognition and the induction of autoimmunity (1999) (111)
Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. (1997) (109)
Combinatorial Peptide Libraries and Biometric Score Matrices Permit the Quantitative Analysis of Specific and Degenerate Interactions Between Clonotypic TCR and MHC Peptide Ligands1 (2001) (109)
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. (2009) (109)
Training-dependent plasticity in patients with multiple sclerosis. (2004) (106)
Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. (1997) (104)
Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS (2001) (104)
Natalizumab treatment perturbs memory‐ and marginal zone‐like B‐cell homing in secondary lymphoid organs in multiple sclerosis (2012) (103)
Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99) (1996) (103)
Therapeutic Potential of Phosphodiesterase-4 and -3 Inhibitors in Th1-Mediated Autoimmune Diseases (2000) (102)
Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis (2016) (101)
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) (2019) (99)
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) (2019) (99)
Borrelia burgdorferi—specific and autoreactive T‐cell lines from cerebrospinal fluid in lyme radiculomyelitis (1988) (98)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Myelin-Associated Oligodendrocytic Basic Protein: Identification of an Encephalitogenic Epitope and Association with Multiple Sclerosis1 (2000) (96)
HTLV‐I‐specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV‐I‐associated neurological disease (1992) (96)
Dendritic cells signal T cells in the absence of exogenous antigen (2001) (96)
HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis (2020) (93)
Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7 (1999) (90)
Functional HLA‐DM on the surface of B cells and immature dendritic cells (2000) (90)
Recognition of Conserved Amino Acid Motifs of Common Viruses and Its Role in Autoimmunity (2005) (88)
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. (2011) (86)
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper (2012) (86)
Genomics in multiple sclerosis—Current state and future directions (2007) (85)
Structure of a TCR with high affinity for self‐antigen reveals basis for escape from negative selection (2011) (84)
Intrathecal effects of daclizumab treatment of multiple sclerosis (2011) (83)
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease (1997) (82)
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. (2003) (82)
Antigen-specific immunomodulation via altered peptide ligands (2001) (81)
Increased serum levels of soluble CD95 (APO‐1/Fas) in relapsing‐remitting multiple sclerosis (1998) (80)
Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation (1992) (79)
Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. (1999) (78)
Immunotherapy of multiple sclerosis: Where are we? Where should we go? (2001) (78)
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. (2011) (78)
TGF-β1-Mediated Control of Central Nervous System Inflammation and Autoimmunity through the Inhibitory Receptor CD261 (2007) (76)
Getting specific: monoclonal antibodies in multiple sclerosis (2008) (75)
Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease. (2001) (74)
Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency1 (2000) (73)
Minimal peptide length requirements for CD4(+) T cell clones--implications for molecular mimicry and T cell survival. (2000) (71)
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. (2012) (71)
A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. (1996) (70)
Meningoradiculitis and encephalomyelitis due to Borrelia burgdorferi: a follow-up study of 72 patients over 27 years (1989) (70)
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy (2021) (69)
Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. (1997) (68)
Human Autoreactive CD4+ T Cells from Naive CD45RA+ and Memory CD45RO+ Subsets Differ with Respect to Epitope Specificity and Functional Antigen Avidity (2000) (67)
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. (2014) (67)
MRI as a marker for disease heterogeneity in multiple sclerosis (2005) (66)
HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. (1990) (65)
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. (2004) (64)
HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype (2005) (63)
Redundancy in Antigen-Presenting Function of the HLA-DR and -DQ Molecules in the Multiple Sclerosis-Associated HLA-DR2 Haplotype1 (2006) (61)
Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones (1998) (61)
Natural triterpenes modulate immune‐inflammatory markers of experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis (2012) (61)
Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis (2013) (60)
JC polyomavirus mutants escape antibody-mediated neutralization (2015) (60)
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. (2005) (60)
T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells (1997) (60)
Myelin basic protein‐specific T‐cell responses in identical twins discordant or concordant for multiple sclerosis (1993) (59)
Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis (1998) (59)
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. (2006) (59)
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: Implications for the initiation of autoimmune response in multiple sclerosis (2005) (58)
Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83–99) (1996) (58)
Autoantigens act as tissue‐specific chemoattractants (2005) (58)
Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. (1997) (56)
GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosis (2018) (56)
Neurological manifestations of coronavirus infections – a systematic review (2020) (55)
Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease. (2014) (53)
Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes (1997) (51)
The good and the bad of neuroinflammation in multiple sclerosis. (2014) (51)
Stem cell transplantation in multiple sclerosis (2008) (50)
Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. (1994) (50)
Ring-enhancement in multiple sclerosis: marker of disease severity (2001) (49)
HLA‐DR‐restricted presentation of purified myelin basic protein is independent of intracellular processing (1997) (49)
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype (2003) (49)
Unique Clinical and Pathological Features in HLA-DRB1*0401–restricted MBP 111–129–specific Humanized TCR Transgenic Mice (2004) (48)
Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients (2013) (48)
Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor Vbeta analysis. (2000) (48)
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis (2012) (47)
FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome (2001) (47)
Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. (2013) (46)
Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years (2002) (46)
Findings on T cell specificity revealed by synthetic combinatorial libraries. (2002) (45)
Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15 (2020) (45)
Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro (2020) (44)
JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment (2013) (44)
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. (2010) (43)
Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype (1997) (43)
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis (2015) (42)
Daclizumab (anti-CD25) in multiple sclerosis (2014) (42)
Disease Progression After Bone Marrow Transplantation in a Model of Multiple Sclerosis Is Associated With Chronic Microglial and Glial Progenitor Response (2007) (41)
Citrulline‐containing myelin basic protein is recognized by T‐cell lines derived from multiple sclerosis patients and healthy individuals (1994) (41)
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis (2009) (41)
Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions (2015) (40)
Broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy (2015) (39)
Use of combinatorial peptide libraries for T-cell epitope mapping. (2003) (39)
Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant (2016) (39)
T cell response to 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in multiple sclerosis patients (2002) (39)
Hsp70 Regulates Immune Response in Experimental Autoimmune Encephalomyelitis (2014) (38)
Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells (2017) (37)
T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft (2010) (37)
Safety of an Ultra-Rush Immunotherapy Build-Up Schedule with Therapeutic Vaccines Containing Depigmented and Polymerized Allergen Extracts (2006) (37)
Immunology of progressive multifocal leukoencephalopathy (2015) (37)
A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis (2019) (36)
HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. (2013) (36)
Antigen-specific tolerization approaches in multiple sclerosis (2014) (35)
Nogo-A Antibodies for Progressive Multiple Sclerosis (2017) (35)
Persistent intrathecal secretion of oligoclonal, Borrelia burgdorferi-specific IgG in chronic meningoradiculomyelitis (1988) (34)
The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells. (2009) (33)
Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. (2003) (33)
Borrelia burgdorferi Induces TLR1 and TLR2 in Human Microglia and Peripheral Blood Monocytes but Differentially Regulates HLA-Class II Expression (2006) (33)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts (2007) (33)
Molecular mimicry in multiple sclerosis (2006) (32)
The initiation of the autoimmune response in multiple sclerosis (2004) (32)
Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology (2017) (32)
2′,3′-cyclic nucleotide 3′-phosphodiesterase: a novel candidate autoantigen in demyelinating diseases (1997) (32)
Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis. (2000) (31)
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life (2014) (31)
Sphingosine-1 phosphate and central nervous system. (2014) (31)
TCR Bias and HLA Cross-Restriction Are Strategies of Human Brain-Infiltrating JC Virus-Specific CD4+ T Cells during Viral Infection (2012) (31)
T helper cell differentiation in multiple sclerosis and autoimmunity. (1998) (31)
Autologous Hematopoietic Stem Cell Transplantation as a Treatment Option for Aggressive Multiple Sclerosis (2013) (30)
Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. (1999) (30)
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: Implications for the initiation of the autoimmune response in multiple sclerosis (2008) (30)
MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis (2019) (30)
Antigen-specific therapies in MS — Current concepts and novel approaches (2008) (29)
Dynamics and heterogeneity of brain damage in multiple sclerosis (2017) (28)
Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis. (2000) (28)
Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae. (2007) (28)
Cerebrospinal Fluid-Infiltrating CD4+ T Cells Recognize Borrelia burgdorferi Lysine-Enriched Protein Domains and Central Nervous System Autoantigens in Early Lyme Encephalitis (2006) (28)
Netrin‐1 and multiple sclerosis: a new biomarker for neuroinflammation? (2017) (27)
Heterogeneity of T-cell receptor alpha-chain complementarity-determining region 3 in myelin basic protein-specific T cells increases with severity of multiple sclerosis. (1994) (27)
Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis (2019) (27)
Spotlight on anti-CD25: daclizumab in MS. (2008) (27)
Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2. (2000) (27)
Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient (2011) (27)
Restoring immune tolerance in neuromyelitis optica (2016) (27)
Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4+ T Cells in Multiple Sclerosis (2019) (27)
Humanized Anti-CD25 Antibody Treatment with Daclizumab in Multiple Sclerosis (2007) (26)
CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis No differences from normal individuals and no relation to HLA-DR2 (1998) (25)
Uptake, biodistribution, and time course of naked plasmid DNA trafficking after intratumoral in vivo jet injection. (2006) (25)
Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: a serial analysis (1996) (25)
Clinically Isolated Neurosarcoidosis: A Recommended Diagnostic Path (2014) (25)
High Production of CXCL13 in Blood and Brain During Persistent Infection With the Relapsing Fever Spirochete Borrelia turicatae (2007) (25)
T Cell Epitope Mapping of JC Polyoma Virus-Encoded Proteome Reveals Reduced T Cell Responses in HLA-DRB1*04:01+ Donors (2013) (25)
CD46 on glial cells can function as a receptor for viral glycoprotein‐mediated cell–cell fusion (2005) (25)
A Multiple Sclerosis–Associated Variant of CBLB Links Genetic Risk with Type I IFN Function (2014) (25)
Detailed Characterization of T Cell Receptor Repertoires in Multiple Sclerosis Brain Lesions (2018) (25)
Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis☆ (1989) (24)
Boswellic acids reduce Th17 differentiation via blockade of IL‐1β‐mediated IRAK1 signaling (2014) (24)
Nogo receptor is involved in the adhesion of dendritic cells to myelin (2011) (23)
The antibody repertoire in experimental allergic neuritis: evidence for PMP-22 as a novel neuritogen (1996) (23)
Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort (2012) (23)
IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis (2013) (23)
Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis (2012) (22)
CD 4 + CD 28 – costimulation-independent T cells in multiple sclerosis (2001) (22)
A functional basis for the association of HLA class II genes adn susceptibility to multiple sclerosis: cellular immune responses to myelin basic protein in a multiplex family (1993) (22)
Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data (2012) (22)
Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis (2010) (22)
Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis (2006) (21)
Restoring immune tolerance in neuromyelitis optica (2016) (21)
Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones (1999) (21)
Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis (2017) (21)
Cystatin F is a biomarker of prion pathogenesis in mice (2017) (21)
Interferon-γ secretion by in vivo activated cytotoxic T lymphocytes from the blood and cerebrospinal fluid during mumps meningitis (1991) (20)
Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases? (2003) (20)
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies (2015) (20)
Longitudinal study of myelin basic protein-specific T-cell receptors during the course of multiple sclerosis (1997) (19)
Nogo-Receptors NgR1 and NgR2 Do Not Mediate Regulation of CD4 T Helper Responses and CNS Repair in Experimental Autoimmune Encephalomyelitis (2011) (19)
A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial) (2017) (19)
Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis (2006) (19)
Antigen-Specific Therapies in Multiple Sclerosis (2005) (19)
A Truncation Variant of the Cation Channel P2RX5 Is Upregulated during T Cell Activation (2014) (18)
Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients (2014) (18)
T-cell response to myelin basic protein and lipid-bound myelin basic protein in patients with multiple sclerosis and healthy donors (1998) (18)
Human T lymphocytes specific for the immunodominant 83–99 epitope of myelin basic protein: Recognition of golli MBP HOG 7 (1996) (17)
Borrelia burgdorferi myelitis presenting as a partial stiff man syndrome (1990) (17)
Future immunotherapies in multiple sclerosis. (2003) (17)
Decrypting the spectrum of antigen‐specific T‐cell responses: the avidity repertoire of MBP‐specific T‐cells (2000) (17)
Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Optic Neuritis (2019) (17)
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. (1997) (17)
Non‐Epstein‐Barr virus‐associated T‐cell lymphoma following cardiac transplantation for Barth syndrome (2001) (17)
A molecular view of multiple sclerosis and experimental autoimmune encephalitis: What can we learn from the epitope data? (2014) (16)
Biomarkers in Multiple Sclerosis (2006) (16)
Effect of Anti-CD 25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis (2009) (16)
Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice. (2016) (16)
An Altered Peptide Ligand Antagonizes Antigen-Specific T Cells of Patients with Human T Lymphotropic Virus Type I-Associated Neurological Disease (2000) (15)
Diversity of T-cell receptor Valpha, Vbeta, and CDR3 expression by myelin basic protein-specific human T-cell clones (1995) (15)
Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting (2016) (15)
Erratum: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β (Proceedings of the National Academy of Sciences of the United States of America (June 8, 2004) 101:23 (8705-8708)) (2004) (15)
Dipeptidyl peptidase IV in inflammatory CNS disease. (2000) (15)
Multiple sclerosis: Immunotherapy (1999) (15)
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis (2021) (15)
Molecular mimicry and multiple sclerosis--a possible role for degenerate T cell recognition in the induction of autoimmune responses. (1999) (15)
Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease. (2000) (14)
Whole Genome Sequencing Reveals a Chromosome 9p Deletion Causing DOCK8 Deficiency in an Adult Diagnosed with Hyper IgE Syndrome Who Developed Progressive Multifocal Leukoencephalopathy (2014) (14)
Multiple sclerosis: doubling down on MHC. (2021) (14)
[Progressive multifocal leukoencephalopathy]. (2016) (14)
GENOMICS IN MULTIPLE SCLEROSISCURRENT STATE AND FUTURE DIRECTIONS (2007) (14)
Immunological questions on hematopoietic stem cell transplantation for multiple sclerosis (2003) (14)
Interstitial pneumonitis associated with sirolimus in liver transplantation: a case report. (2007) (14)
Red wine intake but not other alcoholic beverages increases total antioxidant capacity and improves pro-inflammatory profile after an oral fat diet in healthy volunteers. (2015) (14)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
Multiple sclerosis: Closing in on an oral treatment (2010) (13)
Peptidic complex mixtures as therapeutic agents in CNS autoimmunity. (2004) (13)
Q Fever in Sokoto, Nigeria (1990) (12)
Antigen-Specific Immune Tolerance in Multiple Sclerosis—Promising Approaches and How to Bring Them to Patients (2021) (12)
Subcellular distribution of titanium in the liver after treatment with the antitumor agent titanocene dichloride (1989) (12)
Genetics of multiple sclerosis--how could disease-associated HLA-types contribute to pathogenesis? (1997) (12)
The Orally Available, Synthetic Ether Lipid Edelfosine Inhibits T Cell Proliferation and Induces a Type I Interferon Response (2014) (12)
Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis (2008) (12)
Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15 (2019) (12)
Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration. (1992) (12)
A plea for “Omics” research in complex diseases such as multiple sclerosis—a change of mind is needed (2004) (11)
When T cells recognize a pattern, they might cause trouble. (2006) (11)
Expression pro ® ling identi ® es responder and non-responder phenotypes to interferon-b in multiple sclerosis (2003) (11)
The effect of vesnarinone on TNFα production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis (1999) (11)
Autoimmunity in Lyme disease: molecular cloning of antigens recognized by antibodies in the cerebrospinal fluid. (1989) (11)
Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin‐2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome (2020) (11)
Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells (2015) (10)
Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS (2019) (10)
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS (2021) (10)
T-Cell Epitope Prediction with Combinatorial Peptide Libraries (2003) (10)
Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis (2005) (10)
Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis (2014) (9)
Long-term persistence of specific T- and B-lymphocyte responses to Borrelia burgdorferi following untreated neuroborreliosis (1990) (9)
Mutagenic and genotoxic activities of extracts derived from the cooked and raw edible mushroomAgancus bisporus (2005) (9)
Lack of over-expression of T cell receptor Vβ5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls (1998) (9)
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients (2012) (9)
[The prevalence of multiple sclerosis in the Alcoi Health district]. (2000) (9)
Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones. (2010) (9)
Using stem cells in multiple sclerosis therapies. (2004) (9)
[Neurologic side-effects of pharmacologic corticoid therapy]. (1996) (9)
Biomarkers in multiple sclerosis: an update for 2014. (2014) (9)
Experimental immunotherapies for multiple sclerosis (2004) (8)
Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. (1993) (8)
Is haematopoietic stem cell transplantation a treatment option for severe MS or not? (2007) (8)
Clinical and neuroimmunological findings in chronic Borrelia burgdorferi radiculomyelitis (Lyme disease) (1988) (8)
Chickenpox and multiple sclerosis: a case report. (1995) (7)
Intrathecal synthesis of virus-specific oligoclonal antibodies in patients with enterovirus infection of the central nervous system (1989) (7)
Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis (2022) (6)
In vitro modulation of human, autoreactive MBP-specific CD4+ T-cell clones by cyclosporin A (1997) (6)
Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis (2022) (6)
Is multiple sclerosis progression associated with the HLA-DR15 haplotype? (2019) (6)
HLA class I: friend and foe of multiple sclerosis (2008) (6)
Molecular Basis of Multiple Sclerosis (2010) (6)
Multiple sclerosis: Are HLA class I molecules involved in disease pathogenesis? (1995) (6)
Measurement of polyclonal and antigen-specific cytotoxic T cell function. (2001) (6)
Antibody Titer Determinations against Borrelia burgdorferi in Blood Donors and in Two Different Groups of Patients (1988) (6)
Association of HLA and multiple sclerosis. (1994) (6)
Transfer of Shrimp Allergens to Other Foods Through Cooking Oil (2007) (6)
Different requirements of ICAM‐1/LFA‐1 adhesion in allorecognition and self‐restricted antigen recognition by class II‐specific T cell clones (1994) (5)
Isolation and characterization of Borrelia burgdorferi — specific and autoreactive T cell lines from the cerebrospinal fluid of patients with lyme meningoradiculitis (1987) (5)
Secretion In Vivo β and UpRegulates TGF-Suppresses Autoimmune Encephalomyelitis Targeting Dipeptidyl Peptidase IV ( CD 26 ) (2001) (4)
[Multiple sclerosis incidence in the Alcoi Health district. 12-year-long study (1986-1997)]. (2000) (4)
Central role of Th 2 / Tc 2 lymphocytes in pattern II multiple sclerosis lesions (2015) (4)
Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis (2019) (4)
Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology (2022) (4)
New drugs may improve, complicate treatment for multiple sclerosis (2010) (4)
[Influence of genetic factors on multiple sclerosis]. (1996) (4)
Chronic Central Nervous System Involvement (1993) (4)
Understanding risk of PML through multiple sclerosis (2018) (3)
Different Development of Myelin Basic Protein Agonist- and Antagonist-Specific Human TCR Transgenic T Cells in the Thymus and Periphery1 (2008) (3)
Chapter 53 – Multiple Sclerosis (2003) (3)
Anti-myelin antibody responses following induction of antigen-specific tolerance with antigen-coupled cells (2014) (3)
T Cell Receptor Gene Rearrangements in the Human Response to Myelin Basic Protein (1991) (3)
Limited repertoire of HLA-DRB1*0401-restricted MBP111–129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential (2004) (3)
Identiﬁcation of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone (1997) (3)
Targeting fibrin in neurodegeneration (2018) (3)
Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis (2019) (3)
NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis (2021) (3)
In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study (2018) (3)
Haplotype Multiple Sclerosis-Associated HLA-DR 2 of the HLA-DR and-DQ Molecules in the Redundancy in Antigen-Presenting Function (2006) (2)
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis (2022) (2)
Retransplant Due to Fulminant Hepatic Failure From Hepatitis E Virus: A Case Report. (2018) (2)
Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis (2022) (2)
Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis (2022) (2)
Plaques, T cells and beyond: report on an international meeting on the immunological basis of multiple sclerosis held at the University of Chieti, Italy (1999) (2)
T‐Cell Receptor α and β CDR3 Expression by Myelin Basic Protein‐Specific Human T‐Cell Clones (1995) (2)
[Multiple sclerosis. New therapeutic strategies in the experimental stage]. (1997) (2)
Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis (2022) (2)
Tumor necrosis factor-directed therapy of autoimmune encephalomyelitis by the phosphodiesterase IV inhibitor rolipram (1994) (2)
Immunization with a cannabinoid receptor type 1 peptide results in experimental allergic meningocerebellitis in the Lewis rat: A model for cell‐mediated autoimmune neuropathology (2002) (2)
Specificity of Clones and T Cell Lines from Cerebrospinal Fluid in Viral Meningoencephalitis and Multiple Sclerosis (1987) (2)
From specificity to degeneracy to molecular mimicry: Antigen recognition of human autoreactive and pathogen-specific CD4+ T cells (1998) (1)
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a global approval and availability review (2021) (1)
Natural Triterpenes Modulate Immune-Inflammatory Hallmarks to Protect against Experimental Autoimmune Encephalomyelitis . Therapeutic Implications for Multiple Sclerosis (2015) (1)
T-cell-reactivity against CNPase (a minor myelin component) in multiple sclerosis patients and normals (1994) (1)
FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML) (2020) (1)
Research opportunities on human neuroborreliosis. (2004) (1)
Peptide Ligands T Cells and Induce T Cell Responses to Native + Identify Epitopes That Activate Clonotypic CD4 Immunogenicity. I. Use of Peptide Libraries to (2011) (1)
EBNA1-specifi c T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN- (cid:2) and IL-2 (2008) (1)
Possible pitfalls of an indirect immunofluorescence assay as the sole serological test in the diagnosis of lyme disease (1988) (1)
Correlation with disease severity in multiple sclerosis in CDR3 regions of myelin basic protein-specific T cell receptors (1994) (1)
Peptides as Targets of T Cell-Mediated Immune Responses (2006) (1)
Synthesis and Screening of Positional Scanning Synthetic Combinatorial Libraries (2001) (1)
303 Interleukin 1β production by alveolar macrophages derived from nocturnal asthmatics (1991) (1)
Specificity and Functional Antigen Avidity Subsets Differ with Respect to Epitope + and Memory CD 45 RO + Naive CD 45 RA T Cells from + Human Autoreactive CD 4 (2000) (1)
When a T cell engages a B cell: novel insights in multiple sclerosis. (2020) (1)
Intrathecal production of antibodies against JC virus and other viruses in multiple sclerosis and natalizumab-associated progressive multifocal leukoencephalopathy (2014) (1)
1 CSF-Infiltrating CD 4 + T Cells Recognize Borrelia burgdorferi Lysine-Enriched Protein Domains And CNS Auto-Antigens In Early Lyme Encephalitis (2006) (1)
Pharmacology of Inflammation (2007) (1)
T cell receptor usage in neurological disease: the case in multiple sclerosis (1992) (1)
[Stem cell therapy in multiple sclerosis: a clinical update]. (2009) (0)
Immunological Aspects of Multiple Sclerosis with Emphasis on the Potential Use of Autologous Hemopoietic Stem Cell Transplantation (2019) (0)
Correction: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein (1998) (0)
Using MRI and Optical Coherence Tomography To Dissect Disease Hetrogeneity in Early Relapsing Multiple Sclerosis (P01.164) (2012) (0)
Mechanisms of interferon-beta effect in multiple sclerosis (1996) (0)
Sa.5. The Range of Potential Targets in Antigen-Specific Therapy Are Expanded with Degenerate Autoantigen Recognition By T-Cells (2006) (0)
Genome-wide Scan of 500000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis (2009) (0)
Use-Dependent Plasticity in Patients with Multiple Sclerosis (2004) (0)
Crystal structure of an autoimmune TCR with optimal binding to its self-antigen - an alternative strategy for escaping negative selection (93.32) (2010) (0)
Chemokines in chronic progressive neurological multiple sclerosis (1999) (0)
Roland Martin and of Multiple Sclerosis ? Epstein-Barr Virus : Environmental Trigger (2007) (0)
to Native Peptide Ligands T Cells and Induce T Cell Responses + CD4 Clonotypic to Identify Epitopes That Activate Immunogenicity. I. Use of Peptide Libraries (1999) (0)
Methodological Approach to Identify and Isolate Disease Relevant Brain-infiltrating T Cell Clones in Multiple Sclerosis Patients (2014) (0)
Assessment of a “naive” vs “memory” origin of human autoreactive CD4+ T cell clones specific for myelin basic protein (MBP) (1998) (0)
Platform Presentations (2002) (0)
Multiple Sclerosis T Cells + High-Avidity Myelin-Specific CD 4 Expansion and Functional Relevance of (2004) (0)
Cerebrospinal Fluid Proteomics Signature of Progressive Multifocal Leukoencelophathy in Natalizumab-Treated MS Patients (2014) (0)
MRI Phenotypes As Predictors Of Clinical Outcomes In Patients With CIS in the BENEFIT Population (P1.226) (2014) (0)
Infection T Cells during Viral + Virus-Specific CD 4 Strategies of Human Brain-Infiltrating JC TCR Bias and HLA Cross-Restriction Are Eiermann (2012) (0)
MINIREVIEW Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis? (cid:1) (2007) (0)
Characterization of Highly Stimulatory T Cell Ligands Identified Using Positional Scanning Libraries (2001) (0)
Oral session 30 — Multiple sclerosis (6) (2005) (0)
Both CD4+ and CD8+ T-cell clones infiltrate the brain in a case of bilateral Rasmussen encephalitis (2014) (0)
Sclerosis Epitope and Association with Multiple EncephalitogenicProtein : Identification of an Myelin-Associated Oligodendrocytic (1999) (0)
Adaptive Immune Responses Extracellular Traps Links Innate and T Lymphocyte Priming by Neutrophil (2012) (0)
Immunology of progressive multifocal leukoencephalopathy (2015) (0)
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma (2022) (0)
Longitudinal study of T cell receptor usage to myelin basic protein in multiple sclerosis patients (1994) (0)
DEFIBROTIDE TREATMENT IN PAEDIATRIC PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE INTERIM RESULTS (2020) (0)
Targeting fibrin in neurodegeneration (2018) (0)
Effect of Anti-Allergic Herbal Extract, SA-2121, on the Development of Allergic Conjunctivitis (2006) (0)
Mechanism of Tissue Remodeling in a Murine Model of Chronic Allergic Conjunctivitis (2006) (0)
Oral session 29 — Multiple sclerosis (5) (2005) (0)
Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation (2022) (0)
Interaction of the immunodominant MBP peptide 87-106 with multiple sclerosis-associated HLA DR- and -DQ molecules (1994) (0)
[Current treatment of multiple sclerosis with interferon beta]. (1998) (0)
Multiple Sclerosis-Associated HLA-DR2 of the HLA-DR and -DQ Molecules in the Redundancy in Antigen-Presenting Function (2006) (0)
Cervical spinal cord and brain MRS alterations in normal appearing white matter of multiple sclerosis (MS) patients at 3T (2017) (0)
Use of pharmacogenomics in clinical trials for multiple sclerosis (2008) (0)
The Neurotransmitter NAAG in Different Phases of Relapsing-Remitting Multiple Sclerosis Patients (2019) (0)
The 3A6‐TCR/superagonist/HLA‐DR2a complex shows similar interface and reduced flexibility compared to the complex with self‐peptide (2019) (0)
Community Corner (2008) (0)
Molecular basis of multiple sclerosis : the immune system (2010) (0)
Identification and optimization of antigens for T cell clones of clinical relevance using positional scanning combinatorial libraries (2002) (0)
Use of modified cells to treat multiple sclerosis (2008) (0)
T cell response to myelin basic protein in DR15 Dw2 positive MS patients: Role of DRB5∗0101 and DRB1∗1501 as restriction elements for T cell lines (1994) (0)
AN ALTERED PEPTIDE LIGAND ANTAGONIZES ANTIGEN-SPECIFIC CD8+ CTL IN PERIPHERAL BLOOD OF HAM/TSP PATIENTS (1999) (0)
Chapter 4 Immunology of Multiple Sclerosis (2003) (0)
Viral infections as triggers for CNS autoimmune diseases via molecular mimicry (2008) (0)
Supporting Information The 3 A 6-TCR / superagonist / HLA-DR 2 a complex shows similar interface and reduced flexibility compared to the complex with self-peptide (2019) (0)
Peripheral blood cell bulk cultures are not suitable for the analysis of the genetic control of T-cell cytokine function. (2001) (0)
The TCR/peptide/MHC complex with a superagonist peptide shows similar interface and reduced flexibility compared to the complex with a self-peptide (2019) (0)
New ligands for MHC molecules based on activity patterns of peptide libraries (2002) (0)
The Integration of Positional Scanning Libraries with Bioinformatics and Proteomics (2001) (0)
Autoreactivity against myelin proteins in multiple sclerosis (1998) (0)
Combinatorial peptide libraries and molecular recognition in T-cell mediated immune response (1999) (0)
IL-7 modified primary proliferation asa method for generation of antigen-specific T cell lines (TCL) preferentially from the pool of memory T cells (1998) (0)
Prediction of DR2-restricted T-cell-epitopes within the myelin protein CNPase deduced from known DR2-binding motifs (1994) (0)
The affinity spedrum of myelin basic protein-reactive T cells (1999) (0)
Chapter 6 - Biomarkers in Multiple Sclerosis (2010) (0)
Multiple Sclerosis Support the Etiologic Role of DRB5*01:01 in TCR/HLA-DRB5*01:01 Transgenic Mice Myelin Basic Protein-Specific (2012) (0)
Use of the modified cells for the treatment of ms (2008) (0)
B - T Cell Interactions Activate and Maintain Brain-Homing T Cells in Multiple Sclerosis (2018) (0)
Brain-infiltrating JC virus-specific CD8+ effector T cells counteract CD4+ T cell immune escape of neurotropic JC virus variant (2014) (0)
Faculty Opinions recommendation of Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. (2009) (0)
Receptor CD 26 Autoimmunity through the Inhibitory Nervous System Inflammation and 1-Mediated Control of Central β TGF-and (2007) (0)
EPIDEMIOLOGY AND GENETICS OF MULTIPLE SCLEROSIS (2005) (0)
PWE-066 Clinical features of demyelination during anti-tnf therapy: preliminary outcomes of the pred4 study (2017) (0)
Immunoglobulin G subclass preference of intrathecally produced HIV-specific oligoclonal antibodies (1991) (0)
Cervical spinal cord and brain magnetic resonance spectroscopy alterations in normal appearing white matter of multiple sclerosis (MS) patients at 3T (2017) (0)
Specific immunomodulation in multiple sclerosis by altered peptide ligands (2001) (0)
Future Therapeutic Options for Multiple Sclerosis (2008) (0)
Specific Immunotherapy of Multiple Sclerosis by Altered Peptide Ligands — Risk or Benefit? (2001) (0)
Multiple Sclerosis Polymorphisms in the Susceptibility to Gender-Associated Differences of Perforin (2010) (0)
Chemokines in chronic progressive neurological associated myelopathy and diseases: mu1 t ip le HTLV-1 sclerosis (1999) (0)
Activation of human class-II restricted T cell clones by short peptides (1998) (0)
Correction: Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis (2011) (0)
The affinity spectrum of myelin basic protein-reactive T cells (1999) (0)
the Quality of Early Signaling Events in Human T Thresholds for Effector Function Elicitation, and Relationships Among TCR Ligand Potency, (2017) (0)
Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility? (2017) (0)
A MyelinBasicProteinPeptideIsRecognizedby CytotoxicT CellsintheContextofFourHLA DR 'hypesAssociatedwithMultipleSclerosis (1991) (0)
Individual TCR Signaling Events Ligands : Relationship to the Quality of Down-Modulation by Peptide : MHC Molecule Serial TCR Engagement and (1999) (0)
I-Associated Neurological Disease Human T Lymphotropic Virus Type Antigen-Specific T Cells of Patients with An Altered Peptide Ligand Antagonizes (2000) (0)
Autoimmunity: Basic and clinical science approach complex diseases — new molecules and mechanisms (2006) (0)
T-cell receptor alpha and beta CDR3 expression by myelin basic protein-specific human T-cell clones. (1995) (0)
Crystal structure of 3A6 TCR bound to MBP/HLA-DR2a (2005) (0)
Method for the management of multiple sclerosis (2003) (0)
A method for the treatment of multiple sclerosis (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roland Martin?

Roland Martin is affiliated with the following schools:

Roland Martin's Academic­Influence.com Rankings

Roland Martin's Degrees

Similar Degrees You Can Earn

Why Is Roland Martin Influential?

Roland Martin's Published Works

Published Works

What Schools Are Affiliated With Roland Martin?

Roland Martin's AcademicInfluence.com Rankings